CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola Jane Lawrence, Robert J. Motzer, Richard J. Lee, Rohit K. Jain, Nancy B. Davis, Leonard Joseph Appleman, Oscar B. Goodman, Walter Michael Stadler, Sunil G. Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begona Mellado, Robert A. Figlin, Thomas Powles, Lalith V Akella, Keith W. Orford, Bernard Escudier
Institutions: The University of Texas MD Anderson Cancer Center, University of Utah, Huntsman Cancer Institute, University of Bari Aldo Moro, Auckland City Hospital, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Moffitt Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Pittsburgh Medical Center, Comprehensive Cancer Centers of Nevada, University of Chicago, Fox Chase Cancer Center, Agostino Gemelli University Polyclinic, Hospital Clínic de Barcelona, Cedars-Sinai Medical Center, St Bartholomew's Hospital, Barts Health NHS Trust, Calithera (United States), Institut Gustave Roussy
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Calithera Biosciences
OpenAlex ID: W3168718184